ADMA - ADMA Biologics: Not Immune To Coronavirus Sell-Off Despite Their Ability To Help
ADMA Biologics (ADMA) recently reported their Q4/2019 earnings to reveal an in-line EPS and a slight beat on revenue. Unfortunately, the company released their earnings at the beginning of the Coronavirus Crash and the stock has been beaten down to fresh 52-week lows. Meanwhile, numerous small-cap biotech and biopharma stocks have hit 52-week highs due to their efforts in attempting to contribute to the battle against COVID-19. Sadly, the market has overlooked ADMA and its potential to have a legitimate product.
I intend to review ADMA’s products and how their ASCENIV product could